19
Oversold
Moving averages
SMA 200$1.96-67.97%
Company profile
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
SectorHealthcare
IndustryBiotechnology
Market cap$286.53M
P/E ratioNone
EPS$-0.56
Beta0.784
Dividend yield0.00%
52-week high$4.46
52-week low$0.82
Similar stocks in Biotechnology
BNTX
BioNTech SE
RSI 32
VRTX
Vertex Pharmaceuticals Inc
RSI 43
CRSP
CRISPR Therapeutics AG
RSI 27
IOVA
Iovance Biotherapeutics Inc
RSI 31
DTIL
Precision Biosciences Inc
RSI 45
OCGN
Ocugen Inc
RSI 39
ARCT
Arcturus Therapeutics Holdings Inc
RSI 36
AGEN
Agenus Inc
RSI 44
EDIT
Editas Medicine Inc
RSI 30
ALT
Altimmune Inc
RSI 23
RSI alerts for ALLO
An email when ALLO closes below RSI 30 or above 70. Nothing else.
Data last updated 13 November 2026 at 7:04 AM EST